Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Tax Provisions (2023 - 2025)

Lyra Therapeutics (LYRA) has disclosed Tax Provisions for 3 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Tax Provisions fell 57.14% to $3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $15000.0, a 70.0% decrease, with the full-year FY2024 number at $39000.0, down 33.9% from a year prior.
  • Tax Provisions was $3000.0 for Q3 2025 at Lyra Therapeutics, up from $2000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $17000.0 in Q4 2023 to a low of $2000.0 in Q2 2025.
  • A 3-year average of $9727.3 and a median of $12000.0 in 2023 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: changed 0.0% in 2024, then plummeted 83.33% in 2025.
  • Lyra Therapeutics' Tax Provisions stood at $17000.0 in 2023, then crashed by 64.71% to $6000.0 in 2024, then plummeted by 50.0% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Tax Provisions are $3000.0 (Q3 2025), $2000.0 (Q2 2025), and $4000.0 (Q1 2025).